Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease

[1] Yawn BP(2014)Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members JAMA 312 1033-1048

[2] Buchanan GR(2012)Sickle cell disease in children Drugs 72 895-906

[3] Afenyi-Annan AN(2009)Allogeneic hematopoietic stem-cell transplantation for sickle cell disease N Engl J Med 361 2309-2317

[4] Ballas SK(2012)Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the blood and marrow transplant clinical trials network (BMT CTN) Biology of Blood and Marrow Transplantation 18 1265-1272

[5] Hassell KL(2013)Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling Blood 122 1072-1078

[6] James AH(2011)Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG) Lancet 377 1663-1672

[7] Jordan L(1995)Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia N Engl J Med 332 1317-1322

[8] Lanzkron SM(2006)Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 4 1-20

[9] Lottenberg R(2001)Role of spirituality in patients with sickle cell disease J Am Board Fam Pract 14 116-122

[10] Savage WJ(2000)Reliability and validity of a self-efficacy instrument specific to sickle cell disease Behav Res Ther 38 951-963

[1] Yawn BP(2014)Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members JAMA 312 1033-1048

[2] Buchanan GR(2012)Sickle cell disease in children Drugs 72 895-906

[3] Afenyi-Annan AN(2009)Allogeneic hematopoietic stem-cell transplantation for sickle cell disease N Engl J Med 361 2309-2317

[4] Ballas SK(2012)Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the blood and marrow transplant clinical trials network (BMT CTN) Biology of Blood and Marrow Transplantation 18 1265-1272

[5] Hassell KL(2013)Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling Blood 122 1072-1078

[6] James AH(2011)Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG) Lancet 377 1663-1672

[7] Jordan L(1995)Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia N Engl J Med 332 1317-1322

[8] Lanzkron SM(2006)Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes 4 1-20

[9] Lottenberg R(2001)Role of spirituality in patients with sickle cell disease J Am Board Fam Pract 14 116-122

[10] Savage WJ(2000)Reliability and validity of a self-efficacy instrument specific to sickle cell disease Behav Res Ther 38 951-963